Articles From: A Conservative Model Portfolio for Retirees to AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™


2009/09/17
This mild portfolio is geared toward conservative investors with 10-year time horizons.
Sign-up for A Conservative Model Portfolio for Retirees investment picks
2009/08/27
Low investment balances, relaxed income limits make it worthy of consideration.
Sign-up for IRA Conversion: The Planning Opportunity of the Decade? investment picks
2009/08/07
While funds such as CGM Focus and Fairholme have raked in assets, many of their investors are late to the party.
Sign-up for Did You Do as Well as Your Fund? investment picks
2009/07/09
A top estate-planning attorney shares advice.
Sign-up for Avoid These Estate-Planning Pitfalls investment picks
2009/06/24
The new BGI presents a lot of continuity for iShares and some new opportunities.
Sign-up for Our Take on iShares' New Owner: BlackRock investment picks
2009/05/28
A simple way to set up a custom benchmark.
Sign-up for How Is Your Portfolio Really Doing? investment picks
2009/05/14
How to make sure your financial plan aligns with your personal priorities.
Sign-up for A Top Planner Shares Tips for Retirees and Pre-Retirees investment picks
2009/04/30
Tips for a couple who could lose their safety net.
Sign-up for Preparing a Portfolio for Pension Failure investment picks
2009/04/06
Your step-by-step guide to restoring your asset allocation.
Sign-up for Rebalancing Made Simple investment picks
2009/04/01
Be sure to place your ETF orders effectively.
Sign-up for The Downside of ETF Intraday Liquidity investment picks
2009/03/11
Why fixed-income ETFs traded far from NAV, and how the situation has improved.
Sign-up for Has the ETF Arbitrage Mechanism Failed? investment picks
2009/03/11
Why fixed-income ETFs traded far from NAV, and how the situation has improved.
Sign-up for Has the ETF Arbitrage Mechanism Failed? -- Page 2 investment picks
2009/02/24
We asked for your opinions, and your responses poured in.
Sign-up for Set My Fund Manager Free, Readers Say investment picks
2009/02/03
Question becomes more relevant after market tumbles.
Sign-up for Should Funds Be Allowed to Go to Cash? investment picks
2009/01/22
Too many people are making sucker bets with these products.
Sign-up for Warning: Leveraged and Inverse ETFs Kill Portfolios investment picks
2009/01/22
Too many people are making sucker bets with these products.
Sign-up for Warning: Leveraged and Inverse ETFs Kill Portfolios--Page 2 investment picks
2008/12/30
Tips for ensuring your assets flow to the right people.
Sign-up for How to Handle Beneficiary Designations investment picks
2008/12/11
Tax-loss selling in these accounts is not the slam-dunk that it is for taxable holdings.
Sign-up for Should You Take a Loss in Your IRA? investment picks
2008/12/04
Six reasons to book tax losses and move on.
Sign-up for The Investment Move You Must Make Now investment picks
2008/11/06
This vehicle can lessen the impact of tax increases.
Sign-up for Is the Roth 401(k) Right for You? investment picks
2008/08/12
Tapping into your retirement savings could leave you worse off.
Sign-up for Should You Borrow From Your 401(k)? investment picks
2008/08/07
Harvesting tax losses can reduce your tax bill.
Sign-up for Selling Losers Now Can Improve Your Bottom Line investment picks
2008/04/01
First-quarter results challenge conventional thinking.
Sign-up for Is a Key International-Investing Debate Off the Mark? investment picks
2007/12/13
Lock in your 2007 gains while keeping taxes low.
Sign-up for Harvest Gains in Your Portfolio investment picks
2007/08/09
We explore the unique structure and tax implications of investing in MLPs.
Sign-up for What Is a Master Limited Partnership? investment picks
2007/07/25
Batting Average                                                                                                    Morningstar OptionInvestor editors' best estimate of the probability that a given investment will generate a break even or greater return over our three-year investment horizon.
Sign-up for Option Investing Terms investment picks
2007/05/08
Vanguard seeks approval to offer ETF shares for its actively managed TIPS fund.
Sign-up for A Surprise Entry in the Race for Actively Managed ETFs investment picks
2006/11/13
Investor returns help capture shareholder experience.
Sign-up for How Did Investors Really Do? investment picks
2005/04/05
Eight fine options with a low admission price.
Sign-up for The Best Funds for Entry-Level Investors investment picks
2014/4/12
- In patients with compensated liver cirrhosis and genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, a difficult-to-treat population, TURQUOISE-II demonstrated SVR(12) rates of 91.8 and 95.9 percent after 12 and 24 weeks of treatment, respectively - TURQUOISE-II is the largest phase III study of an all-oral, interferon-free treatment regimen conducted to date exclusively in GT1 HCV patients with cirrhosis - Results from TURQUOISE-II demonstrated high virologic response and similar tolerability profile as seen in GT1 patients in other AbbVie phase III studies - Results from TURQUOISE-II were published online today in The New England Journal of Medicine - AbbVie will also present detailed data from the phase II M12-999 study and phase III PEARL-III study LONDON , April 12, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver
Sign-up for AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™ investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: A Conservative Model Portfolio for Retirees to AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity